See more : Suncall Corporation (5985.T) Income Statement Analysis – Financial Results
Complete financial analysis of Immunocore Holdings plc (IMCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunocore Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- HKR International Limited (0480.HK) Income Statement Analysis – Financial Results
- Edisun Power Europe AG (ESUN.SW) Income Statement Analysis – Financial Results
- Solarpack Corporacion Tecnologica, S.A. (SPK.MC) Income Statement Analysis – Financial Results
- Delta Drone SA (ALDR.PA) Income Statement Analysis – Financial Results
- H&R Century Union Corporation (000892.SZ) Income Statement Analysis – Financial Results
Immunocore Holdings plc (IMCR)
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 249.43M | 143.74M | 26.52M | 30.11M | 25.67M | 23.65M |
| Cost of Revenue | 1.04M | 454.00K | 73.23M | 74.81M | 99.99M | 0.00 |
| Gross Profit | 248.39M | 143.28M | -46.71M | -44.70M | -74.32M | 23.65M |
| Gross Profit Ratio | 99.58% | 99.68% | -176.12% | -148.42% | -289.54% | 100.00% |
| Research & Development | 163.55M | 89.17M | 73.23M | 74.81M | 99.99M | 83.58M |
| General & Administrative | 0.00 | 0.00 | 88.40M | 45.74M | 44.18M | 34.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 99.99M | 83.58M |
| SG&A | 144.50M | 93.72M | 88.40M | 45.74M | 44.18M | 34.16M |
| Other Expenses | 0.00 | -3.00K | 57.00K | -1.15M | 185.00K | 5.60M |
| Operating Expenses | 308.04M | 182.89M | 161.68M | 119.40M | 144.17M | 117.73M |
| Cost & Expenses | 309.08M | 183.34M | 161.68M | 119.40M | 144.17M | 117.73M |
| Interest Income | 17.99M | 3.15M | 47.00K | 706.00K | 1.40M | 822.00K |
| Interest Expense | 5.15M | 7.69M | 5.81M | 3.11M | 3.80M | 842.00K |
| Depreciation & Amortization | 4.09M | 5.34M | 7.59M | 8.98M | 9.21M | 6.71M |
| EBITDA | -51.65M | -38.35M | -166.72M | -102.59M | -113.18M | -86.75M |
| EBITDA Ratio | -20.71% | -25.36% | -509.48% | -250.54% | -419.63% | -342.21% |
| Operating Income | -59.65M | -39.61M | -135.16M | -86.19M | -118.32M | -93.46M |
| Operating Income Ratio | -23.91% | -27.56% | -509.66% | -286.22% | -460.95% | -395.09% |
| Total Other Income/Expenses | -1.24M | 5.79M | 33.66M | -1.17M | -7.87M | 5.28M |
| Income Before Tax | -60.89M | -44.15M | -140.93M | -87.36M | -126.19M | -88.18M |
| Income Before Tax Ratio | -24.41% | -30.71% | -531.40% | -290.10% | -491.60% | -372.78% |
| Income Tax Expense | -5.60M | -2.92M | -9.41M | -13.27M | -22.26M | -16.55M |
| Net Income | -55.29M | -41.22M | -131.52M | -74.09M | -103.93M | -71.63M |
| Net Income Ratio | -22.17% | -28.68% | -495.94% | -246.04% | -404.89% | -302.82% |
| EPS | -1.13 | -0.90 | -3.10 | -2.33 | -3.81 | -2.62 |
| EPS Diluted | -1.13 | -0.90 | -3.00 | -2.33 | -3.81 | -2.62 |
| Weighted Avg Shares Out | 48.89M | 45.71M | 42.49M | 31.78M | 27.31M | 27.31M |
| Weighted Avg Shares Out (Dil) | 48.89M | 45.71M | 43.86M | 31.78M | 27.31M | 27.31M |
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
New Strong Buy Stocks for November 26th
3 Fast-Growing Stocks Analysts See Doubling in Price
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
Immunocore to present at upcoming investor conferences
Immunocore reports third quarter financial results and provides a business update
Immunocore (IMCR) Upgraded to Buy: Here's Why
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports